• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Genetic Alliance, PhRMA initiative for patient-focused drug development

Genetic Alliance, PhRMA initiative for patient-focused drug development

November 11, 2013
CenterWatch Staff

Genetic Alliance, a nonprofit health advocacy organization, and the Pharmaceutical Research and Manufacturers of America (PhRMA) announced an initiative to explore the use of a technology-enabled, crowd-sourcing approach to patient engagement as a complement to ongoing patient-focused drug development efforts under the Prescription Drug User Fee Act (PDUFA V).

The FDA committed to gain the patient perspective on 20 disease areas in public meetings to be held between 2012 and 2017.

After issuing a Request for Proposals, Genetic Alliance chose advocacy organizations representing three disease areas to be the focus of FDA patient-focused drug development public meetings in 2014 and 2015. The patient communities in these three disease areas will pilot a crowd-sourcing, technology-enabled approach to gathering input from a diverse set of patients on key benefit-risk questions.

"Using the Platform for Engaging Everyone Responsibly (PEER), there is an opportunity to demonstrate the power of a secure, crowd-sourced approach to provide additional insight into patients' experience with a disease or condition," said Sharon Terry, president and CEO of Genetic Alliance. "The organizations we selected are expert at broad and diverse engagement from the very people that have a vested interest in patient-focused drug development."

The following organizations were selected to engage the sickle cell disease community:

  • North Alabama Sickle Cell Foundation
  • Sickle Cell Disease Association of America, Southern Connecticut
  • Sickle Cell Warriors
  • The William E. Proudford Sickle Cell Fund

The Coalition for Pulmonary Fibrosis was chosen to engage the idiopathic pulmonary fibrosis community.

The Gastroparesis Patient Association for Cures and Treatments and Share and Care Cockayne Syndrome Network were selected to engage the irritable bowel syndrome, gastroparesis and gastroesophageal reflux community.

Genetic Alliance will provide the participating organizations with a customized version of the PEER system, through which they will engage in a systematic collection of affected individuals' perspectives on a condition's severity and current unmet medical needs.

Private Access is Genetic Alliance's technology partner for this project. Private Access develops participant-centric access controls and privacy management systems. Private Access empowers each individual to set meaningful sharing and privacy preferences that reflect his or her needs and interests.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing